• Arnault, J.P., Wechsler, J., Escudier, B. et al. (2009). Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, 5961.
  • Dougherty, M.K., Müller, J., Ritt, D.A., Zhou, M., Zhou, X.Z., Copeland, T.D., Conrads, T.P., Veenstra, T.D., Lu, K.P., and Morrison, D.K. (2005). Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215224.
  • Flaherty, K., Puzanov, I., Sosman, J., Kim, K., Ribas, A., McArthur, G., Lee, R.J., Grippo, J.F., Nolop, K., and Chapman, P. (2009). Phase I study of PLX4032: proof of concept for V600EBRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27, 15s.
  • Friday, B.B., Yu, C., Dy, G.K., Smith, P.D., Wang, L., Thibodeau, S.N., and Adjei, A.A. (2008). BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68, 61456153.
  • Garnett, M.J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005). Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963969.
  • Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851857.
  • Hall-Jackson, C.A., Eyers, P.A., Cohen, P., Goedert, M., Boyle, F.T., Hewitt, N., Plant, H., and Hedge, P. (1999). Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559568.
  • Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209221.
  • Karreth, F.A., DeNicola, G.M., Winter, S.P., and Tuveson, D.A. (2009). C-Raf inhibits MAPK activation and transformation by B-Raf (V600E). Mol. Cell 36, 477486.
  • Mirzoeva, O.K., Das, D., Heiser, L.M. et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69, 565572.